Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Recruiting Phase 1Phase 2 Interventional

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

NCT00852592
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode
Interventions
7000lux broad-spectrum light, 50lux dim red light
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Melanoma Risk Assessment & Tailored Intervention

NCT01356771
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Surveys & Mailed Materials
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 28, 2026, 10:11 AM EDT
Completed No phase listed Observational

Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke

NCT03618290
View directory record Official record
Conditions
Stroke, Acute
Interventions
Analyze plasma free fatty acid in blood
Diagnostic Test
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 28, 2026, 10:11 AM EDT
Enrolling by invitation Phase 1 Interventional

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

NCT06115642
View directory record Official record
Conditions
Advanced/Metastatic Malignant Solid Tumors
Interventions
HLX43, HLX10
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

NCT00587990
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Lower dose mesenchymal stem cell (MSC) injection, Placebo, Higher dose MSC injection
Biological · Genetic
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

NCT01489813
View directory record Official record
Conditions
Bladder Cancer
Interventions
Genistein, Sugar pill
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 28, 2026, 10:11 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Continuous Cryotherapy in Shoulder Arthroplasty Patients

NCT04861441
View directory record Official record
Conditions
Pain, Shoulder
Interventions
Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler, Icepacks
Device
Lead sponsor
D. Patrick Williams
Other
Eligibility
55 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

NCT04825288
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
30
States / cities
Tucson, Arizona • Burbank, California • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Active, not recruiting Not applicable Interventional

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

NCT01802346
View directory record Official record
Conditions
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
dietary intervention, nutritional support, laboratory biomarker analysis
Dietary Supplement · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

NCT06132841
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 142 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Recruiting Phase 2 Interventional

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

NCT05535166
View directory record Official record
Conditions
Medulloblastoma
Interventions
Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 59 Months
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
10
States / cities
Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

NCT02536183
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
Interventions
Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
Device · Drug
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Don't Throw Your Heart Away: Medical Student Study 2

NCT04176796
View directory record Official record
Conditions
Cardiac Transplant Disorder
Interventions
Stratified Transplant Survival
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

NCT03118466
View directory record Official record
Conditions
AML
Interventions
Etoposide, Cytarabine, Lenalidomide, Mitoxantrone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 10:11 AM EDT
Enrolling by invitation No phase listed Observational

Multi-Institutional IMPACT Validation

NCT06850857
View directory record Official record
Conditions
Facial Injuries, Mandible Fracture, Le Fort, Zygomaticomaxillary Complex Fracture, Nasal Fracture, Orbital Fractures, Zygoma Fracture, Orbital Floor Fracture, Facial Laceration
Interventions
IMPACT-G Module, IMPACT-N Module, IMPACT-O Module, IMPACT-J Module, 15D Control Survey
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

NCT04364802
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Povidone-Iodine Nasal Spray and Gargle
Drug
Lead sponsor
Nikita Gupta
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy

NCT00075842
View directory record Official record
Conditions
Fatigue, Sleep Disorders, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Valeriana officinalis extract, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
33
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 28, 2026, 10:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT02810951
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
FCX-007
Genetic
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 28, 2026, 10:11 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Healthy Volunteer Study

NCT07270783
View directory record Official record
Conditions
Healthy Volunteer
Interventions
D-2570, Placebo
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:11 AM EDT
Enrolling by invitation Not applicable Interventional

Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro

NCT07076277
View directory record Official record
Conditions
Cataract, Multifocal Intraocular Lens
Interventions
Clareon PanOptix Pro and Clareon Vivity Intraocular Lens, Clareon PanOptix Pro Intraocular Lenses
Device
Lead sponsor
Brian Shafer
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Alexandria, Minnesota • Bozeman, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 28, 2026, 10:11 AM EDT